Introduction
Shear stress acting on the endothelial cell apical surface serves as an important signaling mechanism for a variety of cell processes, including stimulated release of vasodilator factors (18; 31; 45) , activation of ion channels in the cell membrane, changes in cellular pH, cell proliferation and vascular remodeling, and cytoskeletal rearrangement with cellular realignment (19; 41) .
Shear or flow-mediated vasodilation is arguably the most important physiological mechanism of vasodilation. It involves stimulated endothelial release of a vasodilating substance such as nitric oxide (NO), prostacyclin or endothelium-derived hyperpolarizing factor (EDHF). Despite the prominence of shear-mediated vasodilation in numerous arterial beds, the initiating signal transduction mechanisms have not been clearly delineated. Shear responsiveness appears greatest in the most rigid non-deformable cellular regions where the stress is highest. In endothelial cells this occurs at the lateral cell-cell junctions (8) . In many vascular tissues shear triggers endothelial release of nitric oxide through a complex pathway involving surface glycoprotein distortion which is transmitted through the endothelial cytoskeleton to the basal membrane at focal adhesions where tyrosine kinases are activated to increase intracellular calcium and activate nitric oxide synthase (5; 34) . It is unclear which cell surface receptors are involved in propagating the shear signal to the underlying cytoskeleton.
Recent evidence suggests that in addition to its role in leukocyte migration, PECAM-1 (CD31) is an important signaling molecule in endothelial cells. It is concentrated at cell junctions(1) in regions highly susceptible to the effects of shear and has been reported to be colocalized with endothelial nitric oxide synthase (eNOS) in the cell membrane (8; 14) . PECAM-1 has also been reported to connect to remote cellular sites through the actin cytoskeleton [reviewed in (35) ], and is tyrosine phosphorylated in response to shear stress (16) . Thus the transmembrane protein PECAM-1 is a logical candidate component of the shear stress signaling pathway involved in flow-mediated vasodilation. In fact recent evidence indicates that PECAM-1 contributes to NO-mediated dilation resulting from rapid changes in flow in skeletal muscle arterioles (2) .
In this study, we examined the effect of PECAM-1 deficiency on the dilation of coronary arterioles in response to application of steady state shear stress. We observed an impairment in shear-induced vasodilation in PECAM-1-deficient relative to wild-type vessels, largely due to a reduction in the endothelium-derived hyperpolarization factor (EDHF)-mediated component of dilation. These findings confirm a modulatory role for PECAM-1 in the signaling pathway for flow-mediated dilation of the coronary circulation.
Materials and Methods

Preparation of mouse Coronary Arteries
Eight-week old male PECAM-1-knock-out (KO) mice that have been backcrossed for >12 generations onto a C57BL/6 background and age-and sex-matched wild type (WT) mice were maintained in a pathogen-free facility of the Animal Resource Center of the Medical College of Wisconsin. All experiments were approved by the local institutional animal care and use committee at the Medical College of Wisconsin.
PECAM-1-KO and WT mice were anesthetized with tribromoethanol (0.4 mg/kg body weight) (Sigma Chemical, St. Louis, MO) intraperitoneally and hearts were removed. Mouse coronary arteries (MCAs) were dissected from the left ventricle of the heart and prepared for videomicroscopy, histofluorescence or immunohistochemistry.
Videomicroscopy
MCAs were cannulated on glass micropipettes in an organ chamber filled with physiological saline solution (PSS) as described previously (33 mol/L) was added to achieve 30-50% constriction. Flow was produced by changing the heights of the reservoirs in equal and opposite directions to generate a pressure gradient. Intraluminal diameter was measured in the presence of flow generated by pressure gradients of 20 and 100 cm H 2 O in the absence and the presence of antagonists. At the end of each experiment, vessels were treated with papaverine (100 µM) to determine the relaxation capacity of the arteriole. All measurements were made at steady state flow achieved 5 minutes after initiating the pressure gradient. Results are expressed as % maximal dilation which was assessed as the change from constricted diameter (U46619) to the largest diameter observed at an intraluminal pressure of 60 mmHg (usually the diameter after treatment with 100 LM papaverine).
To identify the mediators responsible for dilation of MCAs in response to shear stress, pharmacological inhibitors were used. N -nitro-L-arginine methyl ester (L-NAME, 100 Lmol/L), which inhibits nitric oxide synthase (NOS), indomethacin (INDO, 10 Lmol/L), which inhibits cyclooxygenase (COX), or polyethylene glycolated catalase (PEG-CAT), which decomposes hydrogen peroxide, were administered to the vessel chamber after initial measurement of shearinduced vessel dilation, allowing 20-30 minutes incubation prior to measuring the effect of antagonist on the shear-induced dilation response. In some cases sequential time control experiments were performed, which showed that the magnitudes of two consecutive flowinduced dilation responses were similar with no intervening treatment.
In separate experiments, MCAs from each type of mouse were incubated for 24 hours at 37 o C with ebselen (100 Lmol/L, reapplied every 8 hours) dissolved in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum, 100 U/ml penicillin G and 100 µg/ml streptomycin. After the 24 hour incubation, flow-mediated dilation was assessed as described above.
Fluorescence detection of hydrogen peroxide and superoxide.
Dichlorodihydrofluorescein diacetate (DCFH-DA) and hydroethidine (HE) (27) PSS solution, and removed for fluorescence microscopy. DCF (the product of the reaction of DCFH with peroxide) and Oxy-ethidium (oxy-Etd, the fluorescent product of the reaction of HE with superoxide) were excited at 488 nm and 585 nm, and emission was measured at 526 nm and 620 nm, respectively. Fresh untreated (control), and experimental tissues were examined in parallel and images recorded using the same computer-specified gain and intensity settings.
Results are expressed as relative fluorescence intensity of the user defined vessel region, using a vessel treated with PEG-CAT (500 U/ml) and MnTBAP (300 Lmol/L) as a baseline control (where ROS generation is maximally quenched)
Fluorescence detection of nitric oxide production
MCAs were isolated from WT or KO mice and intraluminally exposed to 4,5-diaminofluorescein diacetate (DAF-2) (1 Lmol/L, Molecular Probe), a nitric oxide (NO) indicator, for 15 minutes followed by a wash with PSS solution. Production of NO was examined under fluorescence microscopy at excitation 495 nm and emission 515 nm.
All fluorescence images were analyzed for intensity of fluorescence within a user-defined region of the arteriolar segment (maximal traceable area of the central portion of the vessel).
Artifactual autofluorescent regions were manually eliminated from analysis. Relative average fluorescence intensity was normalized for surface area and compared between control and experimental vessels.
Western blot for detecting unphosphorylated and phosphorylated forms of eNOS
Hearts were removed and homogenized. Protein samples (10 Lg) were loaded onto an 8 % 
Statistics
All data are expressed as mean ± SEM. Percent dilation was calculated as the percent change from preconstricted diameter to the diameter after flow (maximal diameter was measured after papaverine, 10 -4 mol/L). In some cases the L-NAME-sensitive component of dilation was determined by the following calculation: % maximal dilation observed in the absence of inhibitors -% maximal dilation observed in the presence of L-NAME. The indomethacinsensitive component of dilation was calculated as % maximal dilation observed in the presence of L-NAME+INDO -% maximal dilation observed in the presence of L-NAME alone. The residual component, presumably EDHF-mediated, was calculated according to the formula: % maximal dilation observed in the absence of inhibitors -% maximal dilation observed in the presence of L-NAME+INDO. Data from vessels exposed to flow before and after antagonists were compared using a one way ANOVA with repeated measures for pressure gradient and condition (antagonist exposure). The relative fluorescence intensities observed in arterioles from WT or KO mice exposed to static conditions, flow, or acetylcholine (Ach) were compared using a two way ANOVA. All differences were judged to be significant at the level of P<0.05.
Results
Mediators of flow-mediated dilation (FMD) in WT and PECAM-1 KO MCAs: roles of NO, prostaglandins, and EDHF.
We first examined the role of traditional endothelium-mediated dilator substances, NO, prostacyclin, and EDHF, in the coronary arteriolar dilation to shear stress. The baseline diameter of MCAs from WT and KO was 105±8 Lm and 109±8 Lm, respectively. The contractile response to the preconstrictor U46619 was similar in MCAs from WT and KO mice and the dose of U46619 used to constrict WT (60 ± 15 nmol/L) and KO (65 ± 13 nmol/L) animals was similar as well. The magnitude of FMD was reduced in KO relative to WT MCAs (figure 1A, B) (% max. dilation, WT vs KO, 26±3% vs. 11±4% and 68±7% vs. 38±3% at 20 and 100 cm H 2 O pressure gradient, respectively; n=5, P<0.05). The contribution of NO, vasodilator prostaglandins, and EDHF to FMD was determined by the effect of L-NAME, an NO synthase inhibitor, INDO, a cyclooxygenase inhibitor, and a combination of L-NAME and INDO, respectively. The L-NAME-inhibitable portion of dilation to shear stress was similar in WT and KO animals. A slightly greater portion of the dilation, however, was sensitive to indomethacin in WT vs. KO animals. Surprisingly, the remaining, and presumed EDHF, component was abolished in KO MCAs suggesting that the reduced FMD in KO mice is largely due to the loss of EDHF-mediated dilation (figure 1C). FMD in MCAs. PEG-CAT had no effect on FMD in KO MCAs ( figure 2B ). These data demonstrate that the H 2 O 2 component of the dilation to shear stress in MCA, which is detectable in wild type mice, is absent in mice lacking PECAM-1.
Flow increases both O 2
•-
and H 2 O 2 generation in WT but not KO MCAs
The finding that PEG-CAT inhibited FMD of WT but not KO MCAs suggested that KO vessels are unable to either produce H 2 O 2 or respond to H 2 O 2 that is produced normally during shear stress. We therefore evaluated production of H 2 O 2 and its precursor, superoxide anion
), in resting vessels and those exposed to increased flow. As shown in figure 3 , in the absence of flow (resting condition) oxy-Etd and DCF fluorescence intensities, which reflect production rates of superoxide and H 2 O 2 , respectively, were increased in MCAs from KO mice (fold-increase of 4.5±1.6 and 3.5±1.1, respectively) compared to WT (n=4, P<0.05). Flow The production of NO in MCAs from WT or KO mice was determined using DAF-2 fluorescence. Enhanced DAF-2 fluorescence intensity was observed in KO MCAs compared to WT (figure 4A) indicating that NO generation was augmented in KO MCAs. The observed increase in NO formation could be due to increased expression or increased activity of the eNOS enzyme. Total heart eNOS expression levels did not differ between WT and KO mice ( figure 4C lower panel). Therefore enhanced expression of the enzyme does not account for the increase in NO formation. eNOS can be phosphorylated on a serine residue at postion 1117 (pS1177) and on a threonine residue at postion 495 (pT495), with the former correlating with increased and the latter with reduced enzyme activity(4). Heart homogenates showed increased levels of pS1177 in KO compared to WT mice ( figure 4B, n=6, p<0.05 ). In contrast, pT495 levels were similar in KO and WT mice ( figure 4C ). These data suggest that an increase in eNOS activity, but not an increase in eNOS protein levels, contributes to the observed increase in NO formation in PECAM-1 KO relative to WT mice.
Tyrosine nitration is enhanced in PECAM-1 KO coronary arteries. figure 1A) . The proportion of the FMD of ebselen-treated KO vessels that was sensitive to L-NAME and INDO (figure 6A) remained the same as was observed in untreated vessels from KO animals ( Figure 1B) . Therefore the improved FMD that was observed upon ebselen treatment of vessels derived from PECAM-1 KO mice was largely due to restoration of the L-NAME-and INDO-insensitive component of the dilation, which is presumably mediated by EDHF ( figure 6C ). In addition to scavenging peroxynitrite, ebselen can also act as a peroxidase to destroy hydrogen peroxide. We do not believe ebselen is acting in this fashion in the present study since the catalase-sensitive component of dilation was in fact enhanced after treatment of KO vessels with ebselen ( figure 6 ). Overall these data suggest that enhanced ONOO -generation in PECAM-1 KO mice impairs FMD in MCAs by abolishing the bioactivity of H 2 O 2 , the presumed EDHF in mouse coronary arteries.
Discussion
The novel findings of this study are three-fold. First, steady-state FMD was reduced in MCAs of PECAM-1 KO mice. Second, among the vasodilators responsible for FMD in MCA, which include products of NOS and COX as well as EDHF, NOS-mediated dilator mechanisms were not impaired, whereas COX-dependent dilation was slightly reduced and dilation attributable to EDHF was absent in PECAM-1 deficient vessels. Third, levels of NO and O 2
•-
were elevated in PECAM-1-deficient MCAs, accounting for formation of ONOO -, which contributed to the impaired EDHF and COX components of FMD in PECAM-1-deficient vessels. To our knowledge, this study provides the first evidence that PECAM-1 plays a critical role in shear-mediated dilation in the coronary circulation.
The techniques used to obtain the data limit, to some extent, the strength of the conclusions reached in this study. We used fluorescent dyes to assess levels of NO, O 2 production, such as cytochrome C reduction or ESR, respectively, and Western blots for detection of nitrotyrosine residues are not possible due to the very small size of isolated mouse coronary arteries. However, fluorescent methods for ROS detection are highly sensitive (3; 39) and, when simultaneous measurements are made in experimental and control vessels, can accurately detect relative differences in amounts of reactive oxygen species (ROS). We assessed total ethidium fluorescence changes in vessels. Recent experimental data indicate that both ethidium bromide and oxy-ethidium (the product of the reaction of superoxide with hydroethidine) contribute to the fluorescence intensity (11; 46) . Therefore some of the increased fluorescence observed may reflect oxidative products other than superoxide. Similarly, immunohistochemical data, although qualitative, clearly provide evidence for increased ONOO -production in PECAM-1 KO, relative to WT, mouse coronary arteries. Coupled with specific pharmacological approaches to reduce particular ROS, such as our use of ebselen to scavenge ONOO-, these approaches collectively support the conclusion that ONOO-, produced as a consequence of generation of NO and O 2
•-, plays a role in inhibiting the vascular response of PECAM-1-deficient MCAs to shear.
We observed in the present studies that EDHF-and COX-dependent components of FMD could be restored upon treatment of PECAM-1-deficient vessels with the ONOO-scavenger, ebselen. With respect to EDHF, we found in these studies that EDHF-dependent (i.e., NOS-and COX-independent) dilation of MCAs in response to shear was due to the production of H 2 O 2 .
Although we did not provide direct evidence for H 2 O 2 -mediated vascular smooth muscle cell 25) and are therefore candidates for the regulatory effects of PECAM-1 described in this study.
Our findings that NO was present at higher levels and that eNOS was hyperphosphorylated on a regulatory serine residue in PECAM-1 KO relative to WT MCAs and heart lysates, are consistent with the recent report that PECAM-1 associates with and inhibits the activity of eNOS in human umbilical vein endothelial cells (8) . However, the extent to which PECAM-1 associates with and regulates eNOS activity in MCAs is not yet known. We postulate that the increased phosphorylation at S1177 is responsible for the increased basal NO production in PECAM KO mice.
An alternative explanation for the paradoxical findings of increased NO levels and concomitant reduced FMD in PECAM-1 KO MCAs is that attenuated smooth muscle cGMP production lessens dilation in response to NO. To evaluate this possibility, we measured the basal level of cGMP in aortas from WT and KO, since the small size of MCAs precluded their use for this purpose. Preliminary results from studies of four paired KO and WT vessels revealed that aortas behaved similarly to MCAs in that enhanced NO production and upregulation of eNOS pS1177 was observed in KO relative to WT aortas; however, the baseline level of cGMP production was not significantly different in aortas from KO vs. WT mice (data not shown). Future studies are required to expand upon these initial observations and will include measurement of guanylyl cyclase expression, stimulated phosphorylation of eNOS and consequent functional effects. (35)). Tyrosine phosphorylation of endothelial cell PECAM-1 in response to application of fluid shear stress or mechanical stretch has been previously reported (16; 21; 28; 37; 40) . PECAM-1 tyrosine phosphorylation in response to shear has also been shown to correlate with rapid translocation of SHP-2 from its cytoplasmic distribution to the inner face of the endothelial cell plasma membrane (38) . In addition, increases in intracellular calcium, potassium and stretch-activated cation channel opening, and prostacyclin release occur downstream of PECAM-1 engagement on PECAM-1-expressing endothelial cell-like REN cells (15; 36) in a manner that depends on tyrosine phosphorylation sites within the PECAM-1 cytoplasmic domain (20) . It will be important to determine whether PECAM-1 must become tyrosine phosphorylated and bind SHP-2 in order to control endothelial cell production of ROS and thereby influence the ability of vessels to dilate in response to shear stress. immunoreactive bands, in six WT and six KO heart lysates. pS 1177 , but not pT 495 , was significantly elevated in KO relative to WT heart lysates. Figure 5 . Immunohistochemical evidence for peroxynitrite formation in PECAM-1-deficient murine coronary arteries. Anti-3-nitrotyrosine reactivity (index of peroxynitrite formation) was more prominent in coronary arteries from KO relative to WT mice (upper panels). Staining of KO vessels with a non-specific antibody served as a negative control (center panel). Ebselen, a scavenger of peroxynitrite, which had no effect on WT vessel immunostaining, markedly reduced anti-3-nitrotyrosine reactivity in KO arteries (lower panels). Figure 1A ) and restored the ability of KO arteries to dilate in the presence of L-NAME+INDO (compare with Figure 1B) . B. Graphic representation of relative contributions of L-NAME-sensitive (black), INDO-sensitive (white), and residual components (gray; presumably EDHF) to flow-induced dilation in KO murine coronary arteries before (left) and after (right) ebselen treatment. The EDHF-dependent component of flow-mediated dilation was significantly enhanced, whereas the L-NAME-and INDO-sensitive components were unaffected, following ebselen treatment of in KO murine coronary arteries.
Conclusion
